Eyetech To Become Full OSI Subsidiary Under $935 Mil. Deal
OSI's acquisition of Macugen developer Eyetech will pit the company against its Tarceva partner Genentech in the macular degeneration market.
OSI's acquisition of Macugen developer Eyetech will pit the company against its Tarceva partner Genentech in the macular degeneration market.